These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24529377)

  • 1. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
    Croci DO; Cerliani JP; Dalotto-Moreno T; Méndez-Huergo SP; Mascanfroni ID; Dergan-Dylon S; Toscano MA; Caramelo JJ; García-Vallejo JJ; Ouyang J; Mesri EA; Junttila MR; Bais C; Shipp MA; Salatino M; Rabinovich GA
    Cell; 2014 Feb; 156(4):744-58. PubMed ID: 24529377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment.
    Croci DO; Cerliani JP; Pinto NA; Morosi LG; Rabinovich GA
    Glycobiology; 2014 Dec; 24(12):1283-90. PubMed ID: 25117007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
    Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
    Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
    Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
    Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-1 Pulls the Strings on VEGFR2.
    Stanley P
    Cell; 2014 Feb; 156(4):625-6. PubMed ID: 24529367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis.
    Imamaki R; Ogawa K; Kizuka Y; Komi Y; Kojima S; Kotani N; Honke K; Honda T; Taniguchi N; Kitazume S
    Oncogene; 2018 Aug; 37(31):4287-4299. PubMed ID: 29717262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
    Moser C; Lang SA; Stoeltzing O
    Clin Colorectal Cancer; 2007 Jul; 6(8):564-71. PubMed ID: 17681102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I; Kornafel J
    Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF inhibitors in brain tumors.
    Brastianos PK; Batchelor TT
    Clin Adv Hematol Oncol; 2009 Nov; 7(11):753-60, 768. PubMed ID: 20075834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-1 Controls the Proliferation and Migration of Liver Sinusoidal Endothelial Cells and Their Interaction With Hepatocarcinoma Cells.
    Manzi M; Bacigalupo ML; Carabias P; Elola MT; Wolfenstein-Todel C; Rabinovich GA; Espelt MV; Troncoso MF
    J Cell Physiol; 2016 Jul; 231(7):1522-33. PubMed ID: 26551914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
    Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
    Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.